These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242 [TBL] [Abstract][Full Text] [Related]
24. Challenges and promises of developing thrombin receptor antagonists. Yang J; Xu K; Seiffert D Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):162-70. PubMed ID: 20874673 [TBL] [Abstract][Full Text] [Related]
25. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]
26. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075 [TBL] [Abstract][Full Text] [Related]
27. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. Cowley MJ; Kuritzky L Curr Med Res Opin; 2009 Jun; 25(6):1477-90. PubMed ID: 19419337 [TBL] [Abstract][Full Text] [Related]
28. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224 [TBL] [Abstract][Full Text] [Related]
29. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. Leonardi S; Tricoci P; Becker RC Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905 [TBL] [Abstract][Full Text] [Related]
30. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events. Lam S; Tran T Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910 [TBL] [Abstract][Full Text] [Related]
31. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. Gryka RJ; Buckley LF; Anderson SM Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023 [TBL] [Abstract][Full Text] [Related]
32. Atopaxar. A novel player in antiplatelet therapy? Wurster T; May AE Hamostaseologie; 2012; 32(3):228-33. PubMed ID: 22859265 [TBL] [Abstract][Full Text] [Related]
33. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. Leonardi S; Becker RC Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734 [TBL] [Abstract][Full Text] [Related]
34. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403 [TBL] [Abstract][Full Text] [Related]
35. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. Becker RC; Gibson CM; Jennings LK; Morrow DA Am J Cardiol; 2010 Oct; 106(8):S2-3. PubMed ID: 20920638 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Mariani M; Mariani G; De Servi S Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763 [TBL] [Abstract][Full Text] [Related]
37. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both? Mohler ER Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065 [TBL] [Abstract][Full Text] [Related]
38. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867 [TBL] [Abstract][Full Text] [Related]
39. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Leonardi S; Tricoci P; Becker RC Drugs; 2010 Oct; 70(14):1771-83. PubMed ID: 20836572 [TBL] [Abstract][Full Text] [Related]